keyword
MENU ▼
Read by QxMD icon Read
search

early stage lung cancer gene

keyword
https://www.readbyqxmd.com/read/29666445/p52-expression-enhances-lung-cancer-progression
#1
Jamie A Saxon, Hui Yu, Vasiliy V Polosukhin, Georgios T Stathopoulos, Linda A Gleaves, Allyson G McLoed, Pierre P Massion, Fiona E Yull, Zhongming Zhao, Timothy S Blackwell
While many studies have demonstrated that canonical NF-κB signaling is a central pathway in lung tumorigenesis, the role of non-canonical NF-κB signaling in lung cancer remains undefined. We observed frequent nuclear accumulation of the non-canonical NF-κB component p100/p52 in human lung adenocarcinoma. To investigate the impact of non-canonical NF-κB signaling on lung carcinogenesis, we employed transgenic mice with doxycycline-inducible expression of p52 in airway epithelial cells. p52 over-expression led to increased tumor number and progression after injection of the carcinogen urethane...
April 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29666402/expression-of-kk-lc-1-a-cancer-testis-antigen-at-non-tumour-sites-of-the-stomach-carrying-a-tumour
#2
Takashi Fukuyama, Nobue Futawatari, Rui Yamamura, Taiga Yamazaki, Yoshinobu Ichiki, Akira Ema, Hideki Ushiku, Yatsushi Nishi, Yoshihito Takahashi, Toshikazu Otsuka, Hitoshi Yamazaki, Wasaburo Koizumi, Kosei Yasumoto, Noritada Kobayashi
Kita-Kyushu lung cancer antigen-1 (KK-LC-1) is a cancer/testis antigen (CTA) and predominant target for cancer immunotherapy. Our previous study indicated that KK-LC-1 was expressed in 82% of gastric cancers, and also in 79% of early stage of gastric cancers, with a correlation to Helicobacter pylori (H. pylori) infection. In addition, we found that KK-LC-1 was occasionally expressed at non-tumour sites of stomachs carrying tumours. Here, we investigated the characteristics of KK-LC-1 expression at non-tumour sites and the clinical utility of these phenomena...
April 17, 2018: Scientific Reports
https://www.readbyqxmd.com/read/29661164/helicase-like-transcription-factor-expression-is-associated-with-a-poor-prognosis-in-non-small-cell-lung-cancer-nsclc
#3
Ludovic Dhont, Melania Pintilie, Ethan Kaufman, Roya Navab, Shirley Tam, Arsène Burny, Frances Shepherd, Alexandra Belayew, Ming-Sound Tsao, Céline Mascaux
BACKGROUND: The relapse rate in early stage non-small cell lung cancer (NSCLC) after surgical resection is high. Prognostic biomarkers may help identify patients who may benefit from additional therapy. The Helicase-like Transcription Factor (HLTF) is a tumor suppressor, altered in cancer either by gene hypermethylation or mRNA alternative splicing. This study assessed the expression and the clinical relevance of wild-type (WT) and variant forms of HLTF RNAs in NSCLC. METHODS: We analyzed online databases (TCGA, COSMIC) for HLTF alterations in NSCLC and assessed WT and spliced HLTF mRNAs expression by RT-ddPCR in 39 lung cancer cell lines and 171 patients with resected stage I-II NSCLC...
April 16, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29656435/a-multi-omic-study-reveals-btg2-as-a-reliable-prognostic-marker-for-early-stage-non-small-cell-lung-cancer
#4
Sipeng Shen, Ruyang Zhang, Yichen Guo, Elizabeth Loehrer, Yongyue Wei, Ying Zhu, Qianyu Yuan, Sebastian Moran, Thomas Fleischer, Maria Moksnes Bjaanaes, Anna Karlsson, Maria Planck, Johan Staaf, Åslaug Helland, Manel Esteller, Li Su, Feng Chen, David C Christiani
B-cell translocation gene 2 (BTG2) is a tumor suppressor protein and is known to be downregulated in several types of cancer. In this study, we investigated a potential role for BTG2 in early-stage non-small cell lung cancer (NSCLC) survival. We analysed BTG2 methylation data from 1,230 early-stage NSCLC patients from five international cohorts, as well as gene expression data from 3,038 lung cancer cases from multiple cohorts. Three CpG probes (cg01798157, cg06373167, cg23371584) that detected BTG2 hypermethylation in tumor tissues were associated with lower overall survival...
April 15, 2018: Molecular Oncology
https://www.readbyqxmd.com/read/29656111/circulating-histocompatibility-antigen-hla-gene-products-may-help-differentiate-benign-from-malignant-indeterminate-pulmonary-lesions
#5
Smriti Kanangat, Christopher W Seder, Melissa R Pergande, Gabriela C Lobato, Cristina L Fhied, Maryam F Raouf, Michael J Liptay, Jeffrey A Borgia
BACKGROUND: This study explores the potential diagnostic utility of soluble Human Leukocyte Antigen (sHLA) molecules differentially released by lung adenocarcinoma and benign lung lesions. METHODS: Conditioned media from the NSCLC cell lines H358 and H1703 were immunoblotted for soluble isoforms of major histocompatibility complex (MHC) class I (ABC) and II (DRB1, DMB, and DQ) antigens. Sera from 25 patients with benign and 25 patients with malignant lesions were similarly evaluated to appraise the potential diagnostic value...
April 12, 2018: Human Immunology
https://www.readbyqxmd.com/read/29619118/epigenetic-modifications-in-kdm-lysine-demethylases-associate-with-survival-of-early-stage-nsclc
#6
Yongyue Wei, Junya Liang, Ruyang Zhang, Yichen Guo, Sipeng Shen, Li Su, Xihong Lin, Sebastian Moran, Åslaug Helland, Maria M Bjaanæs, Anna Karlsson, Maria Planck, Manel Esteller, Thomas Fleischer, Johan Staaf, Yang Zhao, Feng Chen, David C Christiani
Background: KDM lysine demethylase family members are related to lung cancer clinical outcomes and are potential biomarkers for chemotherapeutics. However, little is known about epigenetic alterations in KDM genes and their roles in lung cancer survival. Methods: Tumor tissue samples of 1230 early-stage non-small cell lung cancer (NSCLC) patients were collected from the five independent cohorts. The 393 methylation sites in KDM genes were extracted from epigenome-wide datasets and analyzed by weighted random forest (Ranger) in discovery phase and validation dataset, respectively...
2018: Clinical Epigenetics
https://www.readbyqxmd.com/read/29587930/-shanghai-pulmonary-hospital-experts-consensus-on-the-management-of-ground-glass-nodules-suspected-as-lung-adenocarcinoma-version-1
#7
Gening Jiang, Chang Chen, Yuming Zhu, Dong Xie, Jie Dai, Kaiqi Jin, Yingran Shen, Haifeng Wang, Hui Li, Lanjun Zhang, Shugeng Gao, Keneng Chen, Lei Zhang, Xiao Zhou, Jingyun Shi, Hao Wang, Boxiong Xie, Lei Jiang, Jiang Fan, Deping Zhao, Qiankun Chen, Liang Duan, Wenxin He, Yiming Zhou, Hongcheng Liu, Xiaogang Zhao, Peng Zhang, Xiong Qin
Background and objective As computed tomography (CT) screening for lung cancer becomes more common in China, so too does detection of pulmonary ground-glass nodules (GGNs). Although anumber of national or international guidelines about pulmonary GGNs have been published,most of these guidelines are produced by respiratory, oncology or radiology physicians, who might not fully understand the progress of modern minimal invasive thoracic surgery, and these current guidelines may overlook or underestimate the value of thoracic surgery in the management of pulmonary GGNs...
March 20, 2018: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/29581842/integrative-proteomic-and-transcriptomic-analysis-provides-evidence-for-trkb-ntrk2-as-a-therapeutic-target-in-combination-with-tyrosine-kinase-inhibitors-for-non-small-cell-lung-cancer
#8
Daniel Richard Gomez, Lauren Averett Byers, Monique Nilsson, Lixia Diao, Jing Wang, Lerong Li, Pan Tong, Mia Hofstad, Babita Saigal, Ignacio Wistuba, Neda Kalhor, Stephen Swisher, Youhong Fan, Waun Ki Hong, Milind Suraokar, Carmen Behrens, Cesar Moran, John Victor Heymach
While several molecular targets have been identified for adenocarcinoma (ACA) of the lung, similar drivers with squamous cell carcinoma (SCC) are sparse. We compared signaling pathways and potential therapeutic targets in lung SCC and ACA tumors using reverse phase proteomic arrays (RPPA) from two independent cohorts of resected early stage NSCLC patients: a testing set using an MDACC cohort (N=140) and a validation set using the Cancer Genome Atlas (TCGA) cohorts. We identified multiple potentially targetable proteins upregulated in SCC, including NRF2, Keap1, PARP, TrkB, and Chk2...
March 6, 2018: Oncotarget
https://www.readbyqxmd.com/read/29571988/mir-192-and-mir-662-enhance-chemoresistance-and-invasiveness-of-squamous-cell-lung-carcinoma
#9
Martyna Filipska, Marcin Skrzypski, Katarzyna Czetyrbok, Tomasz Stokowy, Grzegorz Stasiłojć, Anna Supernat, Jacek Jassem, Anna J Żaczek, Jacek Bigda
OBJECTIVES: Overexpression of miR-192, miR-192* and miR-662 was previously found to correlate with poor prognosis of early-stage squamous cell lung cancer (SCC) patients. In this study, we investigated the relevance of these miRNAs to cancer cell biology and chemoresistance. MATERIALS AND METHODS: MiRNA expression profile was analysed in 10 non-small cell lung cancer (NSCLC) cell lines using RT-qPCR. H520 and H1703 cells were transfected with miRNA inhibitors (anti-miR-192, -192* and -662) for functional studies...
April 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29548588/genetic-variants-in-cytokine-signaling-pathways-and-clinical-outcomes-in-early-stage-lung-cancer-patients
#10
Boris Sepesi, Yuanqing Ye, Kyle G Mitchell, Liren Zhang, Jianchun Gu, Lin Ji, Mara B Antonoff, Wayne L Hofstetter, David C Rice, Reza J Mehran, Garrett L Walsh, Ara A Vaporciyan, Stephen G Swisher, Jack A Roth, Xifeng Wu
OBJECTIVES: The purpose of this study was to explore the role of single nucleotide polymorphisms (SNPs) in cytokine signaling genes and to compare them with clinical outcomes in surgical patients with non-small cell lung cancer (NSCLC). METHODS: SNPs of the cytokine signaling pathway were analyzed using peripheral blood of 722 patients who underwent resection of stage I to III NSCLC between 1995 and 2009. Cox proportional hazard analyses were performed to identify SNPs associated with overall survival (OS) and risk of recurrence...
February 15, 2018: Journal of Thoracic and Cardiovascular Surgery
https://www.readbyqxmd.com/read/29509594/clinical-significance-of-molecular-micrometastasis-in-the-sentinel-lymph-node-of-early-stage-non-small-cell-lung-cancer-patients
#11
Aránzazu Lafuente-Sanchis, Miriam Estors-Guerrero, Ángel Zúñiga, Néstor J Martínez-Hernández, Antonio Cremades, Francisco Aparisi-Aparisi, José M Galbis-Caravajal
OBJECTIVES: Metastatic affectation of lymph node is the main prognostic factor in localized lung cancer. A pathologic study of the obtained samples, even after adequate lymphadenectomy, showed tumor relapses for 20% of stage I patients after oncological curative surgery. We evaluated the prognostic value of molecular micrometastasis in the sentinel lymph node of patients with early-stage lung cancer. PATIENTS AND METHODS: The sentinel node was marked immediately after performing thoracotomy by peritumorally injecting 0...
March 5, 2018: American Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29483918/unique-immune-gene-expression-patterns-in-bronchoalveolar-lavage-and-tumor-adjacent-non-neoplastic-lung-tissue-in-non-small-cell-lung-cancer
#12
Chih-Hsi Scott Kuo, Chien-Ying Liu, Stelios Pavlidis, Yu-Lun Lo, Yen-Wen Wang, Chih-Hung Chen, How-Wen Ko, Fu-Tsai Chung, Tin-Yu Lin, Tsai-Yu Wang, Kang-Yun Lee, Yi-Ke Guo, Tzu-Hao Wang, Cheng-Ta Yang
Background: The immune cells in the local environments surrounding non-small cell lung cancer (NSCLC) implicate the balance of pro- and antitumor immunity; however, their transcriptomic profiles remain poorly understood. Methods: A transcriptomic microarray study of bronchoalveolar lavage (BAL) cells harvested from tumor-bearing lung segments was performed in a discovery group. The findings were validated (1) in published microarray datasets, (2) in an independent group by RT-qPCR, and (3) in non-diseased and tumor adjacent non-neoplastic lung tissue by immunohistochemistry and in BAL cell lysates by immunoblotting...
2018: Frontiers in Immunology
https://www.readbyqxmd.com/read/29473341/expression-and-copy-number-gains-of-the-ret-gene-in-631-early-and-mid-stage-non-small-cell-lung-cancer-cases
#13
Ling Tan, Yerong Hu, Yongguang Tao, Bin Wang, Jun Xiao, Zhenjie Tang, Ting Lu, Hao Tang
BACKGROUND: To identify whether RET is a potential target for NSCLC treatment, we examined the status of the RET gene in 631 early and mid stage NSCLC cases from south central China. METHODS: RET expression was identified by Western blot. RET-positive expression samples were verified by immunohistochemistry. RET gene mutation, copy number variation, and rearrangement were analyzed by DNA Sanger sequencing, TaqMan copy number assays, and reverse transcription-PCR...
February 23, 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29473311/her3-expression-is-enhanced-during-progression-of-lung-adenocarcinoma-without-egfr-mutation-from-stage-0-to-ia1
#14
Toru Kumagai, Yasuhiko Tomita, Shin-Ichi Nakatsuka, Madoka Kimura, Kei Kunimasa, Takako Inoue, Motohiro Tamiya, Kazumi Nishino, Yoshiyuki Susaki, Takashi Kusu, Toshiteru Tokunaga, Jiro Okami, Masahiko Higashiyama, Fumio Imamura
BACKGROUND: Activating EGFR mutations, HER2, and HER3 are implicated in lung cancer; however, with the exception of EGFR gene amplification in lung adenocarcinoma harboring EGFR mutations, their involvement in disease progression during the early stages is poorly understood. In this paper, we focused on which receptor is correlated with lung adenocarcinoma progression in the presence or absence of EGFR mutation from stage 0 to IA1. METHODS: HER2 and HER3 expression and activating EGFR mutations in surgically resected lung adenocarcinoma exhibiting ground glass nodules on chest computed tomography and re-classified to stage 0 and IA1 were examined by immunohistochemistry and peptide nucleic acid-locked nucleic acid PCR clamp method, respectively...
April 2018: Thoracic Cancer
https://www.readbyqxmd.com/read/29464758/a-genomic-and-clinicopathologic-study-of-non-small-cell-lung-cancers-with-discordant-ros1-gene-status-by-fluorescent-in-situ-hybridization-and-immunohistochemical-analysis
#15
Jing Zhao, Xiaotong Chen, J Zheng, M Kong, B Wang, W Ding
BACKGROUND: ROS1 immunohistochemistry (IHC) using D4D6 antibody is a useful tool for screening patients with non-small cell lung cancer (NSCLC) slated for targeted therapy. Many studies and our data have identified cases that express the ROS1 protein strongly but are negative for ROS1 by fluorescent in situ hybridization (FISH). The present study investigated the driver mutation and clinicopathologic characteristics of 26 discordant cases (ROS1 IHC-positive but FISH-negative) to find new clues for distinguishing real ROS1-rearranged cases...
February 21, 2018: Histopathology
https://www.readbyqxmd.com/read/29463557/the-airway-transcriptome-as-a-biomarker-for-early-lung-cancer-detection
#16
Ehab Billatos, Jessica L Vick, Marc E Lenburg, Avrum E Spira
Lung cancer remains the leading cause of cancer-related death due to its advanced stage at diagnosis. Early detection of lung cancer can be improved by better defining who should be screened radiographically, and determining which imaging-detected pulmonary nodules are malignant. Gene expression biomarkers measured in normal-appearing airway epithelium provide an opportunity to use lung cancer associated molecular changes in this tissue for early detection of lung cancer. Molecular changes in the airway may result from an etiologic field of injury and/or field cancerization...
February 20, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29448242/the-lncrna-epel-promotes-lung-cancer-cell-proliferation-through-e2f-target-activation
#17
Seong-Min Park, Eun-Young Choi, Dong-Hyuck Bae, Hyun Ahm Sohn, Seon-Young Kim, Youn-Jae Kim
BACKGROUND/AIMS: Recent studies have revealed that many long non-coding RNAs (lncRNAs) play oncogenic or tumor-suppressive roles in various cancers. Lung cancer is the leading cause of cancer-related death worldwide, and many lung cancer patients frequently relapse after surgery, even those in the early stages. However, the oncogenic or tumor-suppressive roles and clinical implications of lncRNAs in lung cancer have not been fully elucidated. METHODS: The association between an E2F-mediated cell proliferation enhancing lncRNA (EPEL) expression and lung cancer patient survival was accessed using public microarray data with clinical information...
February 9, 2018: Cellular Physiology and Biochemistry
https://www.readbyqxmd.com/read/29445290/molecular-features-of-giant-cell-carcinoma-of-the-lung-a-case-report-and-literature-review
#18
Xin Li, Zihe Zhang, Jinghao Liu, Dan Wang, Sen Wei, Jun Chen
Giant-cell carcinoma of the lung (GCCL) is a rare histological form of poorly differentiated non-small-cell lung cancer, which is classified as a subtype of pulmonary sarcomatoid carcinomas. In this case report, we describe the case of a 50-year-old Chinese male who presented with a pulmonary nodule in the right upper lobe of his lung. After thoracoscopic lobectomy, a histopathologic diagnosis of GCCL was made. He did well postoperatively, showing no local recurrence or distal disease in a 7-year follow-up period...
2018: OncoTargets and Therapy
https://www.readbyqxmd.com/read/29439884/a-quantitative-ct-imaging-signature-predicts-survival-and-complements-established-prognosticators-in-stage-i-non-small-cell-lung-cancer
#19
Juheon Lee, Bailiang Li, Yi Cui, Xiaoli Sun, Jia Wu, Hui Zhu, Jinming Yu, Michael F Gensheimer, Billy W Loo, Maximilian Diehn, Ruijiang Li
PURPOSE: Prognostic biomarkers are needed to guide the management of early-stage non-small cell lung cancer (NSCLC). This work aims to develop an image-based prognostic signature and assess its complementary value to existing biomarkers. METHODS AND MATERIALS: We retrospectively analyzed data of stage I NSCLC in 8 cohorts. On the basis of an analysis of 39 computed tomography (CT) features characterizing tumor and its relation to neighboring pleura, we developed a prognostic signature in an institutional cohort (n = 117) and tested it in an external cohort (n = 88)...
January 10, 2018: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/29435940/mechanism-and-method-for-generating-tumor-free-ips-cells-using-intronic-microrna-mir-302-induction
#20
Shi-Lung Lin, Shao-Yao Ying
Today's researchers generating induced pluripotent stem cells (iPS cells or iPSCs) usually consider their pluripotency rather than potential tumorigenicity. Oncogenic factors such as c-Myc and Klf4 are frequently used to boost the survival and proliferative rates of iPSCs, creating an inevitable problem of tumorigenicity that hinders the therapeutic usefulness of these iPSCs. To prevent stem cell tumorigenicity, we have examined mechanisms by which the cell cycle genes are regulated in embryonic stem cells (ESCs)...
2018: Methods in Molecular Biology
keyword
keyword
17014
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"